Vigabatrin is an epilepsy treatment.
Last updated: 26 March 2020 (11:00am)
We have changed the requirement for automated visual field testing when prescribing vigabatrin, either intially or when renewing the prescription. This change will take effect from 1 April 2020.
Clinicians do not need to do visual field testing if it is impossible or impractical to do so.
Given the current constraints on the health sector, we consider visual field testing may be impossible or impractical.
We anticipate changing the criteria back to its current status once health services have stabilised after the response to COVID-19.
The Special Authority form (SA1907) will be amended as follows:
For initial applications:
2.2 It is impractical or impossible (due to comorbid conditions, or health system capacity constraints) to monitor the patient's visual fields.
For renewal applications:
2.2. It is impractical or impossible (due to comorbid conditions, or health system capacity constraints) to monitor the patient's visual fields.
Who to contact
If you have any questions about this change, email email@example.com
Last updated: 15 April 2020